An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.
Also called NCT07923526
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 400 participants
- Sponsor
- Registry
-
NCT07923526
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07923526. Allocation not applicable; no masking; primary purpose treatment. Start 2027-03 (anticipated); primary completion 2034-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
- Acronym
- SUMMIT OLE
- Condition
- Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
- Intervention (Combination product)
- treprostinil SMI (treprostinil inhalation spray)
- Lead sponsor
- United Therapeutics
Record details
- Record id
cardio:ct-nct07923526- Content hash
bcbec09bd9271e50a30d1449f347b330fca385c582e2958dfd6bf3ec3efa7755